YCT529
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C29H25NO3 |
| Molar mass | 435.523 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
YCT529 is a drug which acts as a potent and selective antagonist of the Vitamin A receptor retinoic acid receptor alpha (RAR-α). In studies on mice it produced a 99% reduction in sperm production, and it has proceeded to early stage human clinical trials as a potential male contraceptive.[1]
The Vitamin A signalling system plays a number of important roles in bodily systems, such as the Immune system “It seems to me inherently unlikely that a compound with such activity would be free of side effects,” says Richard Sharpe, of the University of Edinburgh.[2]
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Cover photo is available under {{::mainImage.info.license.name || 'Unknown'}} license.
Credit:
(see original file).
